Drug interactions
Exenatide injectable + Metformin-sitagliptin
Severity: Moderate
Exenatide injectable and Metformin-sitagliptin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Exenatide is a GLP-1 receptor agonist and sitagliptin is a DPP-4 inhibitor, so both act on the incretin pathway. Combining them adds little extra glucose lowering and is not an established therapeutic strategy. Hypoglycemia risk is low with metformin and these agents unless a sulfonylurea or insulin is also used.
What this interaction means in plain words
Exenatide injectable and Metformin-sitagliptin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
Overlapping incretin-pathway pharmacodynamic effects, with duplicated glucose-lowering action.
What to do
Avoid routine combination of a GLP-1 agonist with a DPP-4 inhibitor and consider stopping sitagliptin if exenatide is used. Monitor blood glucose and GI tolerance, and reduce any concurrent sulfonylurea or insulin dose.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Exenatide injectable and Metformin-sitagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Metformin-sitagliptin
Frequently asked questions
Can I take Exenatide injectable with Metformin-sitagliptin?
MediHelp rates the interaction as moderate. Exenatide injectable and Metformin-sitagliptin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Exenatide is a GLP-1 receptor agonist and sitagliptin is a DPP-4 inhibitor, so both act on the incretin pathway. Combining them adds little extra glucose lowering and is not an established therapeutic strategy. Hypoglycemia risk is low with metformin and these agents unless a sulfonylurea or insulin is also used.
How serious is the interaction between Exenatide injectable and Metformin-sitagliptin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid routine combination of a GLP-1 agonist with a DPP-4 inhibitor and consider stopping sitagliptin if exenatide is used. Monitor blood glucose and GI tolerance, and reduce any concurrent sulfonylurea or insulin dose.
What other medicines interact with Metformin-sitagliptin?
MediHelp also lists interactions of Metformin-sitagliptin with, for example, Clozapine, Contrast media, Diatrizoate meglumine / diatrizoate. The full list is on the Metformin-sitagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
